异基因造血干细胞移植患者的早期和晚期并发症——病例报告
Early and Late Complications in Patients with Allogeneic Transplantation of Hematopoietic Stem Cell - Case Report.
作者信息
Trajkovska Ivana, Georgievski Borce, Cevreska Lidija, Gacovski Andrijana, Hasan Taner, Nedeska-Minova Natasha
机构信息
GOB "8-mi Septemvri" Skopje, Skopje, Republic of Macedonia.
University Clinic of Hematology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
出版信息
Open Access Maced J Med Sci. 2017 May 9;5(3):340-343. doi: 10.3889/oamjms.2017.038. eCollection 2017 Jun 15.
BACKGROUND
Allogeneic hematopoietic stem cells transplantation (HSCT) is a curative intervention in patients with haematological malignant and non-malignant diseases, immunodeficiency, autoimmune, and other genetic diseases. Early complications are complications that are occurring in the first 100 days, while complications arising after the 100th day of transplantation belong to late complications.
CASE REPORT
Forty-nine years old patient with AML treated with allogeneic HSCT from HLA-identical (sister) donor. Ascertained and display of early (acute Graft versus host disease (GvHD) and late complications (chronic GVHD, infections, cataract, secondary malignancy with MS deposits) are made, that emerged after the patient transplantation.
CONCLUSION
Rapidly growing population of patients that undergo allogeneic HSCT creates an obligation to educate patients and physicians about observed late complications that occur after this therapy.
背景
异基因造血干细胞移植（HSCT）是治疗血液系统恶性和非恶性疾病、免疫缺陷、自身免疫性疾病及其他遗传性疾病患者的一种治愈性干预措施。早期并发症是指在移植后100天内出现的并发症，而移植100天后出现的并发症则属于晚期并发症。
病例报告
一名49岁的急性髓系白血病（AML）患者接受了来自 HLA 匹配（姐姐）供体的异基因HSCT。确定并展示了该患者移植后出现的早期（急性移植物抗宿主病（GvHD））和晚期并发症（慢性GVHD、感染、白内障、伴有MS沉积的继发性恶性肿瘤）。
结论
接受异基因HSCT的患者群体迅速增长，这使得有必要对患者和医生进行关于该治疗后观察到的晚期并发症的教育。
Zotero 插件